(Q44181787)

30 November 2017

Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer (English)

1 reference

30 November 2017

Xin-Hua Xu

1

1 reference

30 November 2017

Jin Su

2

1 reference

30 November 2017

Xiang-Yang Fu

3

1 reference

30 November 2017

Feng Xue

4

1 reference

30 November 2017

Qiao Huang

5

1 reference

30 November 2017

Dao-Jun Li

6

1 reference

30 November 2017

Ming-Qian Lu

7

1 reference

30 November 2017

language of work or name

1 reference

16 September 2010

1 reference

Cancer Chemotherapy and Pharmacology

30 November 2017

1 reference

30 November 2017

67

1 reference

30 November 2017

2

1 reference

30 November 2017

475-479

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-010-1450-6

30 November 2017

0 references

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Optimizing first-line treatment options for patients with advanced NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Geriatric oncology: a clinical approach to the older patient with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1450-6

10.1007/S00280-010-1450-6

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference